BX

Bioxyma Sp z. o.o. is a strong opioid-focused subsidiary company founded by Orphinic Scientific S.A. in 2020. Our Company is driven by knowledge, experience, and skills brought by its highly qualified team. 

Bioxyma was formed to foster the development of an innovative therapy based on an analgesic pharmaceutical composition for oral administration, the concept originally sourced from the Medical University of Warsaw.  The new invention is the result of 20 years of experience in the area of pain management and 10 years of intensive work by a team of outstanding scientists led by Professor Magdalena Bujalska-Zadrożny. The project received its first funding from the National Center for Research and Development (NCBiR) in the amount of 10 mln PLN.

Currently, there is an increased number of patients with chronic pain. There is a constant need for stronger solutions for pain management with parallel decreases of adverse reactions. According to a report published in 2019 by the CDC, 65% of Americans aged 65 or above suffered from chronic pain. An important group of opioid users is cancer patients. For those patients in particular, and according to the ladder algorithm, selection of nonopioid, opioid, and adjuvant analgesic therapy should be individualized, as directed by the intensity of the pain. However, chronic opioid intake is associated with severe conditions such as physical dependence or central respiratory depression and milder side effects such as constipation and dizziness which can also influence the daily routine.  

Our goal is to address the global cancer pain market, which generated $5,285 million in 2017 and is projected to reach $7,545 million by 2025, growing at a CAGR of 4.5% from 2018 to 2025.

Based on profound research findings by a team of scientists from the Warsaw Medical University, the innovative combination of opioid and magnesium lactate proved to enhance the analgesic effect. In light of that, Bioxyma is now focused on developing a formulation that will significantly reduce the severity and frequency of common opioid-related side effects. Based on these findings the clinical trials are planned to prove that a combination of oxycodone and magnesium compound besides the enhancement of the analgesic effect, prevents opioid-induced hyperalgesia (OIH), incl. breakthrough cancer pain (BTCP).